Trial · NCT00201123

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123, Phase 2, Completed, NYU Langone Health; results first posted 2014-06-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs. Trials, record NCT00201123. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00201123

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
NCT number: NCT00201123
Status: Completed
Phases: Phase 2
Enrollment: 89 participants, actual
Lead sponsor: NYU Langone Health
Conditions: Tuberculosis, AIDS-related Complex
Interventions: Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
First posted: 2005-09-20
Last updated: 2016-12-16
Results first posted: 2014-06-10

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Sputum Conversion	Measured at 16 Weeks
Secondary	Chest Cavity Size	16 Weeks
Secondary	Bronchoalveolar Lavage (BAL) to Measure Flow of Cytometry and Cytokine Levels	16 Weeks

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Sputum Conversion	Measured at 16 Weeks	Intention to Treat analysis performed. Only subjects excluded were those who did not receive treatment.	percentage of participants	NUMBER
SECONDARY	Chest Cavity Size	16 Weeks	Intention to Treat analysis performed. Only subjects excluded were those who did not receive treatment.	millimeters	MEAN
SECONDARY	Bronchoalveolar Lavage (BAL) to Measure Flow of Cytometry and Cytokine Levels	16 Weeks	Intention to Treat analysis performed. Only subjects excluded were those who did not receive treatment.	cells/mL	MEDIAN

Source ClinicalTrials.gov

Results by group27

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Sputum Conversion	DOTS Control Group		36		percentage of participants
Sputum Conversion	Aerosol Interferon Gamma for TB		60		percentage of participants
Sputum Conversion	Subcutaneous Interferon Gamma for TB		36		percentage of participants
Chest Cavity Size	DOTS Control Group	Baseline	34	Standard Deviation 11	millimeters
Chest Cavity Size	Aerosol Interferon Gamma for TB	Baseline	39	Standard Deviation 24	millimeters
Chest Cavity Size	Subcutaneous Interferon Gamma for TB	Baseline	34	Standard Deviation 13	millimeters
Chest Cavity Size	DOTS Control Group	16 Weeks	20	Standard Deviation 16	millimeters
Chest Cavity Size	Aerosol Interferon Gamma for TB	16 Weeks	29	Standard Deviation 24	millimeters
Chest Cavity Size	Subcutaneous Interferon Gamma for TB	16 Weeks	18	Standard Deviation 17	millimeters
Bronchoalveolar Lavage (BAL) to Measure Flow of Cytometry and Cytokine Levels	DOTS	Lymphocytes Week 0	4	Inter-Quartile Range 2 to 8	cells/mL

1 to 10 of 27Source ClinicalTrials.gov

See all 27 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	DOTS Control Group	32
Overall Study	STARTED	Aerosol Interferon Gamma for TB	32
Overall Study	STARTED	Subcutaneous Interferon Gamma for TB	32
Overall Study	Did Not Meet Continuation Criteria	DOTS Control Group	2
Overall Study	Did Not Meet Continuation Criteria	Aerosol Interferon Gamma for TB	0
Overall Study	Did Not Meet Continuation Criteria	Subcutaneous Interferon Gamma for TB	5
Overall Study	COMPLETED	DOTS Control Group	26
Overall Study	COMPLETED	Aerosol Interferon Gamma for TB	28
Overall Study	COMPLETED	Subcutaneous Interferon Gamma for TB	23
Overall Study	NOT COMPLETED	DOTS Control Group	6

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events9

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
serious	hemoptysis	Respiratory, thoracic and mediastinal disorders	DOTS Control Group	1	30
serious	hemoptysis	Respiratory, thoracic and mediastinal disorders	Aerosol Interferon Gamma for TB	0	32
serious	hemoptysis	Respiratory, thoracic and mediastinal disorders	Subcutaneous Interferon Gamma for TB	0	27
serious	Desaturation on BAL	Respiratory, thoracic and mediastinal disorders	DOTS Control Group	0	30
serious	Desaturation on BAL	Respiratory, thoracic and mediastinal disorders	Aerosol Interferon Gamma for TB	2	32
serious	Desaturation on BAL	Respiratory, thoracic and mediastinal disorders	Subcutaneous Interferon Gamma for TB	2	27
serious	pneumonia	Respiratory, thoracic and mediastinal disorders	DOTS Control Group	0	30
serious	pneumonia	Respiratory, thoracic and mediastinal disorders	Aerosol Interferon Gamma for TB	1	32
serious	pneumonia	Respiratory, thoracic and mediastinal disorders	Subcutaneous Interferon Gamma for TB	1	27

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	DOTS Control Group
Total, all-cause mortality	Aerosol Interferon Gamma for TB
Total, all-cause mortality	Subcutaneous Interferon Gamma for TB
Total, other adverse events	DOTS Control Group	0	30
Total, other adverse events	Aerosol Interferon Gamma for TB	0	32
Total, other adverse events	Subcutaneous Interferon Gamma for TB	0	27
Total, serious adverse events	DOTS Control Group	1	30
Total, serious adverse events	Aerosol Interferon Gamma for TB	3	32
Total, serious adverse events	Subcutaneous Interferon Gamma for TB	3	27

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19753300	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01HL059832	Host Response to TB and AIDS	ROM, WILLIAM N	NEW YORK UNIVERSITY SCHOOL OF MEDICINE	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	1997 to 2006

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00201123

GET https://conductscience.org/api/trials/v1/NCT00201123/results?page=2

API reference For AI assistants